Podcasts about Hatim

Why are external accountability and thoughtful integration of algorithms necessary now to ensure fairer labor dynamics across work environments? What's the puzzling problem that comes with increasing the level of transparency of these algorithms?Hatim Rahman is an Associate Professor of Management & Organizations at Northwestern University in the Kellogg School of Management, and the author of the new book, Inside the Invisible Cage: How Algorithms Control Workers.Greg and Hatim discuss Ratim's book, and his extensive case study of a company matching employers with gig workers, exploring the ways algorithms impact labor dynamics. Hatim draws connections between Max Weber's concept of the 'iron cage' and modern, opaque algorithmic systems, discussing how these systems control worker opportunities and behavior. Their conversation further delves into the evolution and consequences of rating systems, algorithmic transparency, organizational control, and the balance between digital and traditional workforce structures. Rahman emphasizes the need for external accountability and thoughtful integration of algorithms to ensure fairer labor dynamics.*unSILOed Podcast is produced by University FM.*Show Links:Recommended Resources:Control TheoryMax WeberGig EconomyGoodhart's LawRatings InflationFrederick Winslow TaylorFair.workGuest Profile:Faculty Profile at Kellogg School of Management | Northwestern UniversityLinkedIn ProfileHis Work:Inside the Invisible Cage: How Algorithms Control WorkersGoogle Scholar PageFast Company ArticlesEpisode Quotes:Experimenting to find the right balance between regulation and self-regulation33:36: Finding the right balance between self-regulation—where organizations can figure things out for themselves—and real legislation, regulation that creates societal and broader outcomes that are beneficial is where we are right now. Of course, the tricky thing is that you don't want to get that balance wrong either. But, I do think we're at the stage where we need to experiment, right? We need to figure out those optimal levels of transparency, opacity, regulation, and self-regulation.Why employers struggle to recognize and value skills badges from lesser-known institutions39:55: The problem with the skill sets that people develop is that, employers, they didn't understand what it meant. Right? Let's say you have a badge from some smaller university or community college. Employees generally struggle to understand what that means, right? Or they'll pass over it. They'll look for more recognizable, established credentials and proxies for skills. And so, at least when I was studying, many of the workers, employers—like we tried, but it didn't help us because the employer didn't know what it meant or how the passing of that skills test would concretely help them do the job that they required.Why do digital platforms struggle to balance transparency and risk?14:17: Organizations and digital platforms want to find the right balance, but they just struggle a lot to do so because many employers are risk-averse and want to limit their liability. I imagine that this is one of the reasons why they have favored opacity, right? If we don't have to reveal or tell, then it limits our ability to get exposure to lawsuits or exposure to gaming, zone, and so forth.

JCO PO author Dr. Hatim Husain at University of California San Diego, shares insights into his JCO PO article, “Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review”, one of the top downloaded articles of 2024. Host Dr. Rafeh Naqash and Dr. Husain discuss how to utilize real-world and clinical trial data to discern the safety of adagrasib (another KRASG12C inhibitor), following sotorasib discontinuation due to hepatotoxicity. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Stephenson Cancer Center.  Today, I'm very excited to be joined by Dr. Hatim Hussain, Professor of Medicine at the University of California, San Diego, and author of the JCO Precision Oncology article, “Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS-G12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review.” This was one of the top downloaded articles of 2024. And the other interesting thing is we generally don't do podcasts for case reports or case series, so this is one of the very few that we have selected for the podcast.  And at the time of the recording, our guest disclosures will be linked in the transcript.  Dr. Hussain, welcome to our podcast and thank you for joining us today. Dr. Hatim Husain: Thank you Dr. Naqash. Such a pleasure to be here and to speak with you all. Dr. Rafeh Naqash: And for the sake of this podcast, we'll refer to each other using our first names. So again, as I mentioned earlier that this is one of the very few case reports that we have selected for podcasts in JCOPO and the intention was very deliberate because it caters to something that is emerging where we are trying to treat more KRAS mutant patients with different KRAS inhibitors. And you tried to address one very unique aspect of it in this article which pertains to toxicity, especially hepatotoxicity. So for the sake of our listeners who tend to be community oncologists, trainees, academic faculty, can you tell us what are KRAS inhibitors? What is KRAS-G12C? And how do some of these approved KRAS inhibitors try to inhibit KRAS-G12C? Dr. Hatim Husain: Sure. For a long time actually we've not had a selective way to inhibit mutant KRAS. And over the last several years actually now, we've seen some dramatic advances here, particularly with the FDA approval of some of the selective inhibitors against the G12C variant. So KRAS-G12C is an isoform of KRAS that is most common in lung cancer and in fact actually is a transversion mutation in the KRAS gene that is a product of the carcinogen of tobacco. And in fact, the incidence of KRAS-G12C in lung cancer, it's quite astounding where as many KRAS-G12C patients there are, there can be, as you know, more than EGFR patients in certain populations and cohorts. The medicines sotorasib and adagrasib were rationally designed to be selective KRAS-G12C inhibitors. And the way that they do this is that they lock the KRAS protein in the OFF state. KRAS is a protein that oscillates between an ON and an OFF state and by virtue of locking the protein in an OFF state, it has shown inhibition of downstream signaling and mitigation of tumor growth and, in fact, tumor cell death. Dr. Rafeh Naqash: I absolutely love the way you describe the ON and OFF state, the oscillation where the ON is bound to the GTP and the OFF is bound to the GDP. The two KRAS inhibitors as currently FDA approved, as you mentioned, are RAS OFF inhibitors and they're emerging KRAS inhibitors that are RAS ON. So now, as we have known from previous data related to immunotherapy and EGFR TKIs such as osimirtinib where toxicity tends to be a compounded effect when you have osimertinib given within a certain timeline of previous checkpoint therapy, we've seen that in the clinic as the data for these KRAS inhibitors is emerging, you talk about some very interesting aspects and data about what has been published so far with regards to prior use of immunotherapy or chemo immunotherapy and the subsequent use of KRAS inhibitors. Could you elaborate upon that? Dr. Hatim Husain: Sure. So for this population of patients, the first line approved strategy is a strategy that most cases will incorporate immune therapy and chemotherapy. Immune therapy can have some important responses for patients with KRAS-G12C. This may be due to the fact that KRAS-G12C patients may have a higher incidence of prior smoking, perhaps higher mutation burdens in some patients, and perhaps immunogenicity is defined in that context. So the standard of care in the first line currently includes immune therapy or immune therapy and chemotherapy. Where the current FDA approvals for selective G12C inhibitors are are after the first line of therapy. There are a number of trials exploring these medicines in the first line to see if they may be incorporated into a future treatment paradigm. Dr. Rafeh Naqash: Thank you for that explanation. Now, going to what you published in this manuscript, can you help us understand the context of why you looked at this? Even though the data just comprises a case series of a handful of patients, but the observations are very interesting and these are real world scenarios where we often tend to be in situations where an individual has had toxicity on a certain drug and may have some response to that drug, but at the same time, the toxicity is challenging. And then you try to debate whether another drug in the same class might be beneficial without those toxicities. So you've tried to address that to some extent using this data set. So can you elaborate upon the question, the methodology, what you tried to look at, and important observations that you have? Dr. Hatim Husain: Yes, our paper was actually inspired by one of my patients. My patient was a patient who had received chemotherapy and immune therapy and actually in the past, even, you know, additional lines of immune therapies, it was really coming to the edge of where standard treatments would exist. It was right at the same time that these selective inhibitors had been approved and the patient had received sotorasib. And what was remarkable was, when given sotorasib, patient had a very high peak and spike in the transaminases. And we would do different trials of strategies around dose, around interruptions. And it was becoming quite difficult, actually, for the patient to proceed with additional therapy. It was around similar times, actually, and I do want to make a note that the patient was progressing, driven in large fact by the fact that we've had to interrupt the medicine. So we feel and believe that the patient had had inadequate dosing because of the level of toxicity that the patient was having with transaminase increase. So it was around the same time that adagrasib was first commercially available that we were at that point, and we did a trial of adagrasib post-sotorasib, largely driven by necessity, without having additional options to provide this patient in our environment. What was remarkable was when the patient received the adagrasib, there were no spikes in transaminases similar to what we had seen before. And that really led us thinking and to say, “Is this adverse event of transaminase increase or hepatotoxicity, is this a class effect with KRAS-G12C inhibitors, or is it more nuanced than that? Are there different, perhaps, mechanisms by which the medicines may work that may more or less differentially contribute to this adverse event?” And so that inspired us to kind of do a larger analysis, kind of really reach out to a larger network of physicians to gather insights and to gather responses in patients who had had a serial approach of sotorasib and then adagrasib.  What we found in this process was, in fact, actually there were many more cases of patients who resembled my patient, where the sequence of sotorasib going to adagrasib may have demonstrated differential contribution of hepatotoxicity in that context. And that really motivated us to put the publication together to due diligence, and in the publication spend a lot of time to kind of outline each patient case in detail around metrics surrounding time from last immune therapy, the number of days on sotorasib, the best response to sotorasib, the interval between sotorasib and adagrasib, the duration of adagrasib and then the grade of hepatotoxicity seen in each of the contexts, and particularly kind of the adagrasib and patient disease status as well. We were quite inspired by the effort to try to, if we do not have randomized data in comparison of one medicine to another, which we do not at this juncture, we do not have a randomized analysis to really diligently and rigorously compare the rates of AEs across each medicine, and even in sequence, we do not have that with immune therapy. But what we felt was trying to get more analysis of this sequential approach of, if patients had received a medicine, had to be taken off because of toxicity and then actually tried on a new medicine, what were those rates? We felt like that was at least some information to try to get at this question. Dr. Rafeh Naqash: And you bring forward a very important point, which is, a lot of times in the real world setting we don't have cross trial comparisons that can be fully applicable, or we don't have trials that compare two drugs of the same class with respect to the AE profile or efficacy. And observations like the one that you described that led to this study are extremely critical in trying to help answer these questions.  From a data standpoint, and you allude to it to some extent in your manuscript, the trials that are trying to address combination of KRAS-G12C with immunotherapy, especially sotorasib or adagrasib, can you elaborate on that data, what has been published so far and summarize it for our listeners? Dr. Hatim Husain: So there is data from clinical trials looking at patients actually who have received concomitant immune therapy and sotorasib. What was seen in this, in a real world analysis, was that some patients actually who had received sotorasib within a close proximity of immune therapy, as well as a larger study actually which showed in combination there were higher rates of hepatotoxicity in that context. In fact, there were rates of grade 3 hepatotoxicity. And I think built upon that data there's a recognition in the field that we have to be very diligent in terms of even the clinical trial designs in how to understand the pairing between immune therapy and selective G12C inhibitors. There are many trials that are ongoing, one of the studies that is ongoing is known as the KRYSTAL-7 study, which is evaluating adagrasib in combination with pembrolizumab in the first line. And we await more information on that strategy as well. In the context of sotorasib, because of some of the trials that have shown higher rates of hepatotoxicity, there are some additional trials now looking at sotorasib in combination with chemotherapy, and those also have some information that have been reported as well. Dr. Rafeh Naqash: From a drug development standpoint, as you mentioned, there's always a tendency to combine something with something else. And in my practice, and I'm sure in your practice too, when we do early phase trials, many trials are still focused on choosing the maximum tolerated dose, which may be something that we need to gradually move away from as we try to implement these combinations of multiple antibodies plus some of these target agents from maybe the biological optimal dose rather than the maximal tolerant dose is a better way to look at the drugs, the pharmacokinetic profile, and then see what is likely the safest combination with the most appropriate target engagement. Do you have any thoughts on that or insights on that from a drug development perspective? Dr. Hatim Husain: It's a wonderful question and I think it is a very insightful question and understanding of where we are in space right now. And I agree with you that historically, cancer drug development was really hinged upon medicines that perhaps required higher doses to see a benefit or to inch out kind of marginal increases upon where we were at. Now, in combination with medicines that have non-overlapping mechanisms of action, the concept is: Can there actually be more synergy across an approach using combinatorial strategies rather than just additive effects? And I think that in some cases this is being studied with immune therapy, in some cases actually even in the context of other novel mechanisms for cancer therapy. I think that in my practice, I will really try to see how a patient at an approved dose will respond. But definitely I'm open to the concept that there may be a dose that doesn't have to be the maximally tolerated dose, but rather the dose that responses can be seen and perhaps actually at a lower dose than what drives many toxicities. Dr. Rafeh Naqash: I often describe this to my patients as individual patient dose optimization outside of a clinical trial, where I'm sure you've probably done this, where in older adults maybe a lower dose of osimertinib is tolerated better, or a lower dose of sotorasib or adagrasib for that matter, tolerated better with perhaps a similar level of efficacy, since we don't have comparisons between doses and efficacy so far.  So I think in the bigger picture, as we discussed in a nutshell, what I would really like the listeners to understand is as we try to move towards this field of precision medicine targeting more and more of the undruggable genes, there's bound to be a certain level of toxicity patterns that we'll start observing. So I think these real world scenarios which may not be addressed using clinical trials because it is in the real world setting where you cycle one treatment after another after another, which may or may not be allowed in most trials and the real world setting can inform, in certain cases, subsequent trial designs. So I think the most important message, at least that I took from your manuscript, was that these real world observations can make a huge difference and inform practice, even though the data sets may be small. Of course, you want to validate some of these findings in a bigger, broader setting, but proof of concept is there. And I think next time I see an individual in my clinic where I see better toxicity, I'll definitely try to talk to them about subsequent treatment with another KRAS inhibitor, maybe adagrasib or something else, if and when appropriate.  Do you have any closing thoughts on some of these things that we discussed? Dr. Hatim Husain: I just want to leave the audience actually with this concept that sometimes we group targeted therapy side effects as being class effects unanimously. And I do think actually that each inhibitor may have different off target effects on where medicine may act. We don't truly understand the mechanism of hepatotoxicity in the context of selective KRAS-G12C inhibitors. One of the hypotheses may be due to off target cysteine reactivity in the numerous off target binding sites that certain medicines may have over others. And just even qualitatively which off target binding sites there may be, and how that may lead to either immunogenic responses and other organs or such. So I do think that we do need more research to understand the mechanism. But I think where we are at right now in this space is not assuming that all medicines are going to have the exact same toxicity. I think especially when patients may not have other options, this is something to consider as well. Dr. Rafeh Naqash: Thank you so much. Now, outside of the scientific insights, Hatim, I know you a little bit from before. And knowing the kind of work that you've done in precision medicine, I'm really interested to know about where you started, how you started, how things have been, and what kind of advice you have for junior faculty fellows who are interested in this field of precision medicine that is becoming more and more exciting as we progress in the oncology space. Dr. Hatim Husain: Thank you, Rafeh. I will say, actually as a medical student, I was actually very interested in oncology, partly because it was then and still remains one disease or a constellation of diseases that just has such a high psychological burden on patients. And through the experiences I've had, I really can understand and relate with that concept. I did my medical school at Northwestern, residency at the University of Southern California, and then my oncology fellowship at Johns Hopkins University.  And now I've been on faculty at University of California, San Diego, for about 12 years now. It's been a great experience paralleled with the fact that during these last 12 years, I've really seen how the developments in precision oncology, both targeted therapy as well as immune therapy, have really blossomed and unfolded. A large area of my research in my career has kind of focused on cancer genome and integration of novel technologies to really see how they may have clinical application. When I was in my fellowship and as a young faculty, the liquid biopsy was actually coming into development. And this was hinged upon information that had come forward in the prenatal space where some patients actually who were undergoing prenatal testing during pregnancy were found to have complex karyotypes and genomic alterations and then retrospectively found to have cancer.  And doing my fellowship at Johns Hopkins, some of the pioneers in liquid biopsy were my mentors and really kind of instilled in me that passion for really thinking through how cancer genomics can be integrated through time. And some of the research that I have been doing has been looking at clonal evolution of cancer, how cancer is changing over time, and how we can think through the right surveillance strategies to really understand how that change is occurring. The dynamics of ctDNA in retrospective cohorts have been studied and shown that, you know, there can be associations between progression-free survival and other clinical endpoints. The current paper that we are speaking about parallels that in a certain way where, rather than say, looking at clonal evolution and say, the efficacy answer of sotorasib first and then adagrasib and how frequently can adagrasib salvage patients, this looks at it from a different angle around toxicity. And I think that is a key point because, at my core, I really do enjoy the clinical aspect of complex decision making on behalf of patients weighing efficacy and toxicity that they may have as they try to get the best quality of life through this journey. Dr. Rafeh Naqash: Thank you again, Hatim, for all those insights, both from the scientific perspective as well as personal perspective. We appreciate that you chose JCOPO as the destination for your work.  And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Hatem Husain Disclosures Consulting or Advisory Role: AstraZeneca, Foundation Medicine, Janssen, NeoGenomics Laboratories, Mirati Speakers' Bureau: AstraZeneca, Janssen Institution Research Funding: Pfizer, Bristol-Myers Squibb, Regeneron, Lilly Travel, Accommodations, Expenses: AstraZeneca, Janssen, Foundation Medicine  

TUTAMÉIA faz a leitura do relato do que aconteceu na data de hoje, há um ano, na visão do escritor Atef Abu Saif, autor de "Quero Estar Acordado Quando Morrer", editado pela Elefante, que autorizou a produção deste trabalho. Atef Abu Saif nasceu no campo de refugiados de Jabalia, na Faixa de Gaza, em 1973. Formou-se na Universidade de Birzeit, na Cisjordânia, com estudos de pós-graduação na Universidade de Bradford, Inglaterra, e no Instituto Universitário Europeu de Florença, Itália. É autor de cinco romances e dois livros de contos, além de ensaios políticos, como The Drone Eats with Me [O drone almoça comigo] (Comma, 2015) e A Suspended Life [Uma vida em suspenso] (Al-Ahleya, 2015). Colabora frequentemente com jornais e revistas árabes, além de já ter publicado no New York Times e no Guardian, entre outros meios de comunicação ocidentais. Já foi porta-voz do partido político Fatah e, em 2019, mudou-se para Ramallah, onde atuou até março/24 como ministro de Cultura da Autoridade Nacional Palestina. Ele estava em Gaza cumprindo uma agenda de trabalho quando grupos da resistência armada palestina realizaram uma série de ataques ao território israelense, prontamente respondidos por Israel com todo seu poderio militar. Encurralado na estreita faixa territorial sob intenso bombardeio junto com seu filho, parentes e outros 2,3 milhões de compatriotas, Atef começou a escrever — e escreveu todos os dias até que conseguiu sair de Gaza, quase três meses depois. “Quero estar acordado quando morrer” é resultado desse diário do genocídio, publicado simultaneamente por editoras de dez países. Inscreva-se no TUTAMÉIA TV e visite o site TUTAMÉIA, https://tutameia.jor.br, serviço jornalístico criado por Eleonora de Lucena e Rodolfo Lucena. Acesse este link para entrar no grupo AMIG@S DO TUTAMÉIA, exclusivo para divulgação e distribuição de nossa produção jornalística: https://chat.whatsapp.com/Dn10GmZP6fV...

In this episode of "Sleepless in Singapore," I take you on a journey to South Africa with my adventurous friend Hatim. Our escapade begins in Cape Town, where we accidentally dine and dash on our first night, only to return and pay, much to the relief of the waitstaff. The next day, we explore the stunning Cape Point, marvel at the powerful ocean, and visit an ostrich farm (sadly without Marty), where we feed the birds and take countless photos. Our adventure continues with a visit to the South African Penguins, an evening at a sushi bar, and a trip to the vibrant Victoria and Alfred Waterfront. The following days are a whirlwind of experiences: from an insightful slum tour to the breathtaking Kirstenbosch National Botanical Garden, where we admire unique African flora. We indulge in ice cream at Tapi Tapi, enjoy a dramatic drive through the mountains to a secluded Airbnb, and savor a traditional braai under a starlit sky. Our journey wraps up with a visit to Stellenbosch's wineries, a Segway tour, and a final night of local food and dance in Cape Town.

This week on CounterSpin: The power of the algorithm is ever clearer in our lives, even if we don't understand it. Algorithms don't just guess at what you might like to buy: sometimes they're determining whether you get a job, or keep it. Some 40 million people in the U.S. use online platforms to find work. The algorithms these platforms use create an environment where organizations enact rules for workers' behavior, reward and sanction them based on that, but never allow workers to see these accountancies that make their lives unpredictable, much less work with them to develop measurements that would be meaningful. Hatim Rahman has been working on this question. He's assistant professor of management and organizations at the Kellogg School of Management at Northwestern University, and he's author of a new book about it: Inside the Invisible Cage: How Algorithms Control Workers, forthcoming in August from University of California Press. Plus Janine Jackson takes a quick look back at recent press coverage of climate disruption.   The post Hatim Rahman on Algorithms' “Invisible Cage” appeared first on KPFA.

Algorithms create an environment where organizations enact rules for workers' behavior, reward and sanction them based on that, but never allow workers to see these accountancies.

Zineb Hatim est une figure marocaine de l'entrepreneuriat qui a fait preuve de sa détermination et de son engagement pour promouvoir les compétences marocaines à l'étranger et aux Maroc et créer des opportunités pour les entrepreneurs marocains. Dans cet épisode, Zineb nous parle en détail de son parcours et de son engagement avec Maroc Entrepreneur. Elle explique comment elle a grandi, les expériences qui l'ont menée à s'impliquer dans cette association, et les objectifs qu'elle poursuit à travers cette organisation. En outre, elle partage des informations précieuses sur le fonctionnement de Maroc Entrepreneur, en décrivant les initiatives et les projets en cours, ainsi que les défis rencontrés et les succès obtenus. Elle nous offre une vision approfondie de la mission de l'association et de son impact sur la communauté entrepreneuriale marocaine. Episode of Driss Jabar Join us for more inspirational content on: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Send in a voice message: https://podcasters.spotify.com/pod/show/sara-zri/message

In this episode of "Sleepless in Singapore," I recount a trip across Southeast Asia with Hatim, starting with a lucky break on a ferry from Koh Tao to Chumphon. We accidentally found ourselves in a plush seating area without paying extra, a nice little win that kicked off our adventure. The trip was a mix of comfort, confusion over local names, and the joy of unexpected freebies. From there, we embarked on a train journey filled with friendly chats, even with language barriers, and the quirky charm of traveling through Thailand by rail. The adventure continued with us navigating through Thailand, sampling local food (even when it meant accidentally ordering chicken feet), and dealing with police checkpoints in a way that turned potential hassles into fun stories. The trip wasn't just about moving from place to place; it was about the people we met, the sights we saw from the back of a scooter in Chiang Mai, and the peaceful days spent on a boat down the Mekong River. Despite the occasional discomfort and the laughable moments of misunderstanding, it was the kind of journey that brings stories to life, connecting us more deeply to each other and the world around us.

In this episode of "Sleepless in Singapore," I take you along the first leg of a journey from Singapore to Laos, venturing through Malaysia, Thailand, Laos and almost touching the edge of Cambodia, before flying back home. This trip is a deep dive into some of the beauty of Southeast Asia, marked by the decision to travel light. After a hefty trip to Japan loaded with camera gear, Hatim and I opt for minimalism, packing just a small backpack each. This choice transforms our travel experience, allowing us to move freely and immerse ourselves fully in every moment, from sipping coffee in Malacca to exploring the Cameron Highlands. The essence of this journey lies not just in the places we visit but in the experiences we gather along the way. From a stolen but recovered GoPro to the simplicity of traveling with just a few essentials, the trip is a collection of small adventures that weave into a rich tapestry of memories. Each destination, from the hustle of Georgetown to the tranquility of Koh Tao, offers its own unique flavor.

In this episode of "Sleepless in Singapore," I delve back into my Kenya trip with a story about our safari adventure. The day kicks off with a bit of drama at the hotel over unsettled bills, before we rush to catch our train. The train station surprises us with its airport-like security checks, where a small company-branded Hanso pocket knife in my luggage causes some trouble. Thanks to Hatim's quick thinking and a small "token of friendship" to the security, we're on our way – pondering over how big the "tokens of friendship" would have to be for more serious contraband. Our safari journey is the real highlight, starting with a warm welcome by Maasai warriors and a ride in open-top Land Cruisers that sets the tone for an unforgettable experience. The campsite is luxurious, blending comfort with the raw beauty of the savannah. From cold eucalyptus-scented towels to gourmet meals under the stars, every detail is a treat. The wildlife encounters, serene landscapes, and moments of camaraderie with friends make this safari an absolute dream. It's a tale of adventure, unexpected comforts, and the sheer joy of discovering Kenya's natural wonders. The story rounds off with our last day spent in Dubai, a stark contrast of city life to the savannah's tranquility.

In this fifth episode of "Sleepless in Singapore," I take you on a whirlwind adventure to Kenya, sparked by a my friend Hatim's unique African Indian wedding, a detour through Dubai, and the logistical puzzle of getting there from Singapore. The journey involves meticulous flight planning, a brief but packed stopover in Dubai—complete with a less-than-ideal airport experience and a SIM card surprise—and a leap into the vibrant, albeit chaotic, welcome of Kenya. The flights, ranging from the comfort of Singapore Airlines to the surprising pleasantness of flydubai, set the stage for a series of events that promise cultural immersion and the warmth of rekindled friendships. The journey then transitions smoothly into Kenya, where the wedding festivities await. The anticipation builds with every flight segment, and the narrative weaves through the complexities of travel, the nuances of international friendships, and the universal excitement of attending a wedding—a celebration that transcends borders and cultures, setting the scene for an episode filled with adventure, connection, and discovery. I'll dive into the second leg of our adventure in the next episode, where we embark on an unforgettable safari, encountering zebras, lions, and a host of incredible wildlife, followed by a relaxing weekend at Chale Island and a whirlwind, yet fascinating, 12-hour sightseeing layover in Dubai.

In this episode of "Sleepless in Singapore," I share our recent trip to Vietnam, prompted by an invite to my friend Hatim's elaborate Indian wedding in Kenya. Residing in casual-dress Singapore, I am in dire need of an array of formal and cultural wear for the event. On a recommendation from my gym trainer Bryan, Nat and I spontaneously fly to Da Nang, Vietnam, to visit Bong Tailor in Hoi An, a city renowned for its tailoring expertise. Our visit is a delightful blend of shopping for tailor-made suits and experiencing the rich culture and cuisine of Hoi An and Da Nang. The adventure also includes a whimsical sightseeing tour, featuring a charming ox ride and a traditional boat trip. A visit to Ba Na Hills is a unique experience, with its surreal European-themed architecture creating a quirky, yet enjoyable atmosphere. Sampling local delicacies, like bagels and homemade ice cream, adds to the richness of our journey. Sharing these moments on my podcast, I aim to offer my listeners a peaceful escape, leading them gently towards a restful night.

In this episode of "Sleepless in Singapore," I share our recent trip to Vietnam, prompted by an invite to my friend Hatim's elaborate Indian wedding in Kenya. Residing in casual-dress Singapore, I am in dire need of an array of formal and cultural wear for the event. On a recommendation from my gym trainer Bryan, Nat and I spontaneously fly to Da Nang, Vietnam, to visit Bong Tailor in Hoi An, a city renowned for its tailoring expertise. Our visit is a delightful blend of shopping for tailor-made suits and experiencing the rich culture and cuisine of Hoi An and Da Nang. The adventure also includes a whimsical sightseeing tour, featuring a charming ox ride and a traditional boat trip. A visit to Ba Na Hills is a unique experience, with its surreal European-themed architecture creating a quirky, yet enjoyable atmosphere. Sampling local delicacies, like bagels and homemade ice cream, adds to the richness of our journey. Sharing these moments on my podcast, I aim to offer my listeners a peaceful escape, leading them gently towards a restful night.

Mishary Rashid al Afasy Kuran Hatim

Kuran Hatim 2 Sheikh Mishary Al Afasy

Kuran Hatim 1 Sheikh Mishary Al Afasy

Kuran Hatim 3 Sheikh Mishary Al Afasy

I met with Nathan Cassereau and Hatim Bourfoune from IDRIS, a national computing centre for the CNRS (the national research centre in France). Nathan and Hatim work on the Bloom project, an open source large language model, which was created using the Jean-Zay supercomputer. Thanks to Nathan and Hatim I had the chance to take a look at the machine after our interview. LLMs and AI/ML in general have created a lot of excitement. Hatim said he got into AI/ML himself, and he highlighted a Coursera course run by Andrew Ng. Here are a few links:https://arxiv.org/abs/2211.05100 a paper on BLOOM on ArXivhttps://github.com/ncassereau-idris/lm-evaluation-harness Evaluation of LM https://github.com/dptrsa-300/start_with_bloom Getting started with BLOOM on GitHubhttps://huggingface.co/bigscience/bloom Summary on BLOOM from Huggingface https://www.technologyreview.com/2022/07/12/1055817/inside-a-radical-new-project-to-democratize-ai/ a technology review on BLOOM by MIThttps://towardsdatascience.com/run-bloom-the-largest-open-access-ai-model-on-your-desktop-computer-f48e1e2a9a32 another BLOOM articlehttps://www.youtube.com/@CNRS-FIDLE YouTube channel by CNRS https://github.com/NVIDIA/Megatron-LM Megatron LM library used in the projecthttps://github.com/microsoft/DeepSpeed DeepSpeed library used in the projecthttps://pytorch.org PyTorch library https://www.genci.fr/en a national infrastructure to provide access to HPC (Grand Equipement National de Calcul Intensif) in Francehttps://en.wikipedia.org/wiki/Jean_Zay brief summary of Jean Zay's lifehttp://www.idris.fr/eng/jean-zay/jean-zay-presentation-eng.html The Jean Zay supercomputer at IDRIS/Paris-Saclay Support the Show.Thank you for listening and your ongoing support. It means the world to us! Support the show on Patreon https://www.patreon.com/codeforthought Get in touch: Email mailto:code4thought@proton.me UK RSE Slack (ukrse.slack.com): @code4thought or @piddie US RSE Slack (usrse.slack.com): @Peter Schmidt Mastadon: https://fosstodon.org/@code4thought or @code4thought@fosstodon.org LinkedIn: https://www.linkedin.com/in/pweschmidt/ (personal Profile)LinkedIn: https://www.linkedin.com/company/codeforthought/ (Code for Thought Profile) This podcast is licensed under the Creative Commons Licence: https://creativecommons.org/licenses/by-sa/4.0/

This episode focuses on the topic of AI education and workforce transformation with Dr Hatim Abdulhussein, National Clinical Lead for AI and Digital Workforce at NHS England Key discussion topics include: - The NHS England strategy for AI education for the healthcare workforce - 5 healthcare workforce AI archetypes: Shapers, Drivers, Creators, Embedders and Users - The role of workforce transformation from AI MDT teams to the professionalisation of the digital and data professionals and the creation of new leadership roles in technology and AI.  Developing healthcare workers' confidence in AI: https://digital-transformation.hee.nhs.uk/building-a-digital-workforce/dart-ed/horizon-scanning/developing-healthcare-workers-confidence-in-ai Artificial Intelligence (AI) and Digital Healthcare Technologies Capability framework: https://digital-transformation.hee.nhs.uk/building-a-digital-workforce/dart-ed/horizon-scanning/ai-and-digital-healthcare-technologies?

This episode, I speak with Hatim Rahman, an Assistant Professor of Management and Organizations at Northwestern University's Kellogg School of Management.   In our conversation today, we talk about a recent paper he published in AMJ, with co-authors, about digital labor platforms and how experimentation by platform designers can impact worker autonomy. I also talk with Hatim about the current state of employer-labor relations and the future impact of digital platforms on employment including a prediction that might already be true by the time this podcast airs.   Anchor Paper: Rahman HA, Weiss T, Karunakaran A. forthcoming. The Experimental Hand: How Platform-Based Experimentation Reconfigures Worker Autonomy. Academy of Management Journal https://journals.aom.org/doi/10.5465/amj.2022.0638 

Riyya our Adversary Adee ibn Hatim's (ra) father only received fame/repute for his generosity (Ahmad). Imam Muawaih (ra) weeps uncontrollably when he hears about a Hadith (3 men who enter Hell), then recites Surah 11 v15-16. Seek repentance for deeds done for other than Allah SWT to avoid punishment (Ibn Qayeem). Knowledge is The Seed, The deed is the Field, Sincerity is its water (Ihya).

Bekel Mukim

Welcome back to the "Light of Reflection" podcast! In this episode, we delve into a transformative dialogue between Dr. Hatim and a non-Shia Muslim scholar. Witness the power of combining logic with knowledge as we tackle 14 pivotal questions about Shia Islam. From understanding the Prophet's unique role to the significance of Imam Ali's succession, this conversation promises to enlighten and challenge your perspectives. Whether you're a born Shia or someone curious about the faith, this episode offers a logical sequence to deepen your understanding. Subscribe for more insightful discussions and stay tuned for our upcoming book based on this dialogue.

Beat the censors, sign-up for our newsletter: 
https://firstfreedoms.ca/call_to_action_pages/stay_informed/  
 This is part two of a two-part interview with Marty Moore and Hatim Kheir. 
 In this discussion, these men discuss the impact of government restrictions on religious gatherings and how it took center stage. Highlighting the challenges posed by indoor and outdoor limitations, the Justice Centre for Constitutional Freedoms (JCCF) emerged as a key player in challenging these restrictions. Both participants emphasized the need to scrutinize the reasonableness of such measures, citing the duty of the courts to uphold Canadians' constitutional freedoms. The conversation went into the vital role of the courts in preventing governmental overreach and safeguarding citizens' rights.  
 Despite a seeming “pause” in restrictions, ongoing legal battles prove the importance of organizations like JCCF, which continue to support those adversely affected. The debate over the necessity of restrictions saw government experts and opposing voices at odds. Comparisons with the United States shed light on differences in how religious freedom is treated.  
 While the U.S. defended these freedoms robustly, some argue that Canada appears to place less value on them. The conversation probed whether our society prioritizes prosecuting religious leaders over addressing underlying issues. The lack of care and respect for individual freedoms was a recurring concern. Marty Moore and Hatim Kheir voiced a shared sentiment: Canada is a nation worth fighting for, with constitutional principles that must be upheld to ensure the well-being and freedom of its citizens. 
 Please note the views expressed by the individual(s) in this video are their own, and do not necessarily reflect the views or principles of the First Freedoms Foundation.

 Check out Marty & Hatim's information links below: 
Marty:
 Website: jccf.ca  
 LinkedIn: https://www.linkedin.com/in/marty-moore-53b149187/  
 Hatim:
 Website: jccf.ca 
 Twitter: https://twitter.com/Hatim_Kheir_

Beat the censors, sign-up for our newsletter:  https://firstfreedoms.ca/call_to_action_pages/stay_informed/  This is part one of a two-part interview with Marty Moore and Hatim Kheir. In a time of unprecedented challenges, Marty Moore and Hatim Kheir continue to be defenders of constitutional rights through their work at the Justice Centre. As the weight of restrictions imposed by the provincial health officer fell over British Columbia, Marty Moore, a constitutional lawyer, represented several churches who challenged the government's prohibition on church gatherings and protests.  Moore shares with Barry the significant breaches of freedom of conscience and religion, highlighting the disheartening reality that the courts are consistently showing deference to the government. Meanwhile, in Ontario, Hatim Kheir had his own case  journey dealing with similar issues as he represented the Alymer Church of God and the Bible Chapel. Challenging Ontario's gathering restrictions, Hatim Kheir faced a court of appeal's decision upholding government restrictions as constitutional.   The Supreme Court of Canada refused to hear both of these cases which means the lower court decisions remain in the governments favour. While the court has historically delved into contentious public policy issues, this time, its silence has left questions unanswered. This shift poses a significant concern for the future. Please note the views expressed by the individual(s) in this video are their own, and do not necessarily reflect the views or principles of the First Freedoms Foundation. Check out Marty & Hatim's information links below: Marty: Website: jccf.ca   LinkedIn: https://www.linkedin.com/in/marty-moore-53b149187/  Hatim: Website: jccf.ca  Twitter: https://twitter.com/Hatim_Kheir_

Beat the censors, sign-up for our newsletter: https://firstfreedoms.ca/call_to_action_pages/stay_informed/ This is an interview with Hatim Kheir and Jojo Ruba, two passionate voices advocating for freedom of expression and the power of open dialogue. Hatim, a lawyer representing Free to Care's intervention in the Bill Whatcott case, tackled the controversial issues raised in the case. Hatim, Jojo, and Barry discussed the importance of vigilance against repeating historical mistakes against freedom of speech and the need to push back when it is being challenged today. In this evolving legal landscape, courts' views have shifted, recognizing the delicate balance between critique and hate. Barry and his guests discussed the challenges arising from the misconception that criticizing behavior equates to hating individuals. Jojo's dedication to confronting relativism—a belief in the absence of objective truth—became a central theme in this interview. They emphasized the importance of showing up and engaging in conversations that shape society's future. Both Hatim and Jojo recognize the broader implications: that it's not just freedom of expression at stake, but the core of who we are and how we interact with one another. As courts continue to evolve and society faces complex issues, their efforts remind us to safeguard the right to speak out while fostering understanding and progress. Check out Hatim and Jojo's information below: Hatim: Website: jccf.ca  Twitter: https://twitter.com/Hatim_Kheir_  Jojo:  Website: https://www.freetocare.ca/staff  Twitter: https://twitter.com/JojoRRuba?s=20 

In this Quartertones event in collaboration with Habibi Festival held at Joe's Pub, we talked to classical pianist Hatim Belyamani and rapper Mehdi WMD.ABOUT HABIBI FESTIVALCreated with the goal of giving a snapshot of contemporary and traditional musics of the SWANA (South West Asia North Africa) region, Habibi Festival aims to take listeners on a journey of the sounds wafting through the airwaves and living rooms of cities spanning Marrakech to Baghdad to Brooklyn. This new performing arts festival is a collaboration between the Director of Joe's Pub at the Public Theater Alex Knowlton, artist/composer/curator Yacine Boulares, and curator/producer Meera Dugal who are bonded by the goal of creating more joyful spaces for performance, conversation, and storytelling from this part of the world. Learn more at www.habibi-festival.com. Created by Mikey Muhanna, afikra Hosted by Meera Dugal, Habibi FestivalEdited by: Ramzi RammanTheme music by: Tarek Yamani https://www.instagram.com/tarek_yamani/About Quartertones:QuarterTones is a music show. It is an opportunity to listen to music, across genres, from musicians of and from the Arab world. This series is similar to NPR's All Songs Considered that is focused on the Arab world. afikra will be inviting musicians of all genres, as well as music historians, to help better understand the music that they perform or study. In this series, the guests will be invited to talk about their work and play their music, whether live or recorded, in three segments. The series will host current musicians who play contemporary and modern, including alternative scene or hip-hop, electronic, classical music, among other genres. The musicians will also be from different geographies.Join the live audience: https://www.afikra.com/rsvp   FollowYoutube - Instagram (@afikra_) - Facebook - Twitter Support www.afikra.com/supportAbout afikra:‎afikra is a movement to convert passive interest in the Arab world to active intellectual curiosity. We aim to collectively reframe the dominant narrative of the region by exploring the histories and cultures of the region- past, present, and future - through conversations driven by curiosity. Read more about us on  afikra.com

Justice Centre lawyer Hatim Kheir joins Kevin to give his wrap-up after the final week of testimony at the Public Order Emergency Commission hearing in Ottawa. We get Hatim's impressions and observations from his front row seat at the proceedings. There was plenty of drama throughout, culminating in the much anticipated appearance of Prime Minister Justin Trudeau. We discuss the late unredactions of government documents and highlight some significant admissions by the PM and his ministers. POEC: Exhibits, Presentations and ReportsThe National Post, Nov 25, 2022: 'A bit anti-climactic': Trudeau delays start of Emergencies Act inquiry, strolls in latePOEC, Nov 25, 2022: Day 31 of Public HearingsRex Murphy in The National Post via MSN, Nov 23, 2002: Trudeau's national 'emergency' was a pure concoction of political convenienceBrian Lilley in the Toronto Sun via MSN, Nov 24, 2022: Trudeau government won't share secret legal basis for invoking Emergencies ActCCLA, Nov 25, 2022: CCLA reacts to Prime Minister Trudeau's testimony at POECJustice Centre on Youtube, Nov 23, 2022: Day 29 - Kittredge cross-examines AnandMr.caulker on Youtube, Nov 25, 2022: Sujit Choudhry, Counsel for CCF Confronts Trudeau "The Most Open Prime Minister" on Blank DocumentsJustice Centre on Youtube, Nov 25, 2022: Day 31 - Chipiuk cross-examines TrudeauJustice Centre on Youtube, Nov 25, 2022: Day 31 - Chipiuk delivers the summary statementJustice Centre on Youtube, Nov 25, 2022: Day 21 - Kheir cross-examines Vigneault, Tessier and ChayerNoé Chartier on Twitter, Nov 24, 2022: "Freeland's notes brought by Miller are from the call with the bank executives. It's not her suggesting to list protesters as terrorists, but a bank exec named "Dave."Justice Centre on Youtube, Nov 24, 2022: Day 30 - Miller cross-examines FreelandThe National Post via MSN, Nov 24, 2022: Trudeau cabinet casually discussed crushing Freedom Convoy with tanksFront Page, Nov 25, 2022: Biden Admin Pushed Trudeau to Crack Down on Freedom ConvoyCanadian Press via CBC, Oct. 31, 2022: Doug Ford overstates privilege in trying to avoid testifying at Emergencies Act inquiry, commissioner saysTheme Music "Carpay Diem"Support the show

Friday November 18, 2022 Rabi 'ath-Thani 23, 1444   Eight Lessons in Thirty-Three Years: The Life Lessons of Imam Hatim al-Asamm

Kevin speaks with Justice Centre lawyer Hatim Kheir, who is working with the team that has standing at the Public Order Emergency Commission hearing in Ottawa. The hearings are examining the government's justification for invoking the Emergencies Act to end the Freedom Convoy protest last February. Hatim has been posting daily updates on witness testimony, and here he gives his round-up for the week. As well, he has some insight into what he sees coming in the week ahead.Public Order Emergency CommissionJustice Centre's Youtube Channel (with daily updates by Hatim Kheir)Rebel News, Nov 10, 2022: Coutts protester facing 10 years in prison testifies | Recapping Trucker Commission Day 19True North, Nov 9, 2022: Coutts blockade made up of “neighbours”, supported by residents, says mayor | Day 20 Recap of Emergencies Act hearingsRebel News, Nov 11, 2022: Coutts mayor describes blockade protesters as 'domestic terrorists' | Recapping Trucker Commission Day 20Andrew Lawton Show on True North, Nov 9, 2022: The Andrew Lawton Show | Trudeau told Ford police didn't need more “tools” to deal with protestsGlobe and Mail, Nov 9, 2022: More than 100 tow truck companies refused to help RCMP clear Coutts blockade, document saysTrue North, Nov 10, 2022: Day 21 Recap of Emergencies Act hearings | No concerns about convoy crime, says govt officialRebel News, Nov 9. 2022: Trudeau was annoyed he could not put political pressure on OPP during the Windsor blockadeToronto Star, Nov 10, 2022: Tow truckers told RCMP they were paid to refuse help clearing Alberta border blockade, Emergencies Act inquiry hearsOttawa Citizen, Feb 10, 2022: Federal government tried to 'wash its hands' of responsibility in convoy protests: Ontario deputy ministerPOEC Webcast, Nov 19, 2022: Day 19 - Alan Honner cross-examines OPP's Dana Earley (starts at 2:28:40)Justice Centre on Youtube, Nov 10, 2022: Day 21 - Miller cross-examines DegrandTheme Music "Carpay Diem" by Dave StevensSupport the show

In this fascinating conversation with Leon Fontaine, lawyer Hatim Kheir explains his work on cases pertaining to the ArriveCAN app, and other pandemic restrictions. He says many experts see Digital IDs as a potential technological threat to Canadians' Charter rights and freedoms.  Don't forget to become an insider to get all the latest updates and more from Leon. If you enjoy this podcast, please like, subscribe, and leave a review. 

IVM LIKES IS NOW POP WRAP! And for this episode we have something special to talk about.There's one thing that everyone can agree on, television in 90s and early 2000s was much better than what it is now. Shararat, Power Rangers SPD, Hatim, surely, these ring a bell and take you back to your childhood.In this episode of Pop Wrap! Antariksh and Snayhil are joined by Pragati as they talk about Nostalgia Television. Tune into this episode for a nostalgia trip to your childhood shows and much more. Have topics or things that you'd like for us to cover on the show? Reach out to us on InstagramFollow Antariksh on Instagram: https://instagram.com/antarikshtFollow Snayhil on Instagram : https://instagram.com/snayhilFollow Pragati on Instagram : https://www.instagram.com/pragati.ganeriwalYou can listen to this show and other awesome shows on the IVM Podcasts app on Android: https://ivm.today/android or iOS: https://ivm.today/ios, or any other podcast app.

Le lundi à 20h, l'émission qui vous plonge chaque semaine au cœur du Rodez Aveyron Football en compagnie d'un joueur ou d'un dirigeant du club.

In dit 1-2tje gaat Brian in gesprek met de man achter het JB Football Coach concept. Hatim Akarom speler van KRC Mechelen, vertelt hoe dit is ontstaan & welk pad hij al heeft afgelegd in zijn carrière

I'm honored to host the great inventor and entrepreneur Dr. Hatim Zaghloul Who invented WiFi technology along and paved the road for 4G and 5G technologies by his patents in WOFDM (Wide-band Orthogonal Frequency Division Multiplexing) technology in my Program The Founder on Cairo Business Radio In Part 3, We are speaking about How can you register your invitation and why it is important to do so ? يعد اليوم علامة فارقة في تاريخ برنامجي حيث استضفت الدكتور حاتم زغلول العالم ورائد الاعمال المصري مخترع تكنولوجيا الواي فاي وغيرها من تكنولوجيات الاتصالات الحديثة You can follow my channels via the below link https://linktr.ee/fadyismaeel

I'm honored to host the great inventor and entrepreneur Dr. Hatim Zaghloul Who invented WiFi technology along and paved the road for 4G and 5G technologies by his patents in WOFDM (Wide-band Orthogonal Frequency Division Multiplexing) technology in my Program The Founder on Cairo Business Radio In Part 4, Dr Hatem shares his pearls of wisdom for entrepreneur and investors? يعد اليوم علامة فارقة في تاريخ برنامجي حيث استضفت الدكتور حاتم زغلول العالم ورائد الاعمال المصري مخترع تكنولوجيا الواي فاي وغيرها من تكنولوجيات الاتصالات الحديثة You can follow my channels via the below link https://linktr.ee/fadyismaeel

I'm honored to host the great inventor and entrepreneur Dr. Hatim Zaghloul Who invented WiFi technology along and paved the road for 4G and 5G technologies by his patents in WOFDM (Wide-band Orthogonal Frequency Division Multiplexing) technology in my Program The Founder on Cairo Business Radio In Part 2, We are speaking about Enteopreunr characteristics. What does invention mean? How can you benefit of it ? يعد اليوم علامة فارقة في تاريخ برنامجي حيث استضفت الدكتور حاتم زغلول العالم ورائد الاعمال المصري مخترع تكنولوجيا الواي فاي وغيرها من تكنولوجيات الاتصالات الحديثة You can follow my channels via the below link https://linktr.ee/fadyismaeel

I'm honored to host the great inventor and entrepreneur Dr. Hatim Zaghloul Who invented WiFi technology along and paved the road for 4G and 5G technologies by his patents in WOFDM (Wide-band Orthogonal Frequency Division Multiplexing) technology in my Program The Founder on Cairo Business Radio In Part 1, We are knowing who is Dr. Hatim Zaghloul? How did he start his journey? What is his Motto? يعد اليوم علامة فارقة في تاريخ برنامجي حيث استضفت الدكتور حاتم زغلول العالم ورائد الاعمال المصري مخترع تكنولوجيا الواي فاي وغيرها من تكنولوجيات الاتصالات الحديثة You can follow my channels via the below link https://linktr.ee/fadyismaeel

From Egypt to North America, Dr. Hatem Zaghloul is a global success story. We are honored to have him on CBR to share his expertise.

Pour ce 3ème épisode, Afrique Résonance poursuit son voyage à la rencontre de personnalités inspirantes et vous fait découvrir Hatim Ben Ahmed, Co-fondateur et Managing Partner chez Mediterrania Capital Partners. Crée en 2013, Mediterrania Capital Partners est une société de capital-investissement dont la stratégie est focalisée sur la croissance des PME et ETI en Afrique, avec un total d'actifs sous gestion de plus de 450 millions d'euros. La firme s'illustre dans de nombreux secteurs avec notamment des participations dans la santé au Maroc (Akdital), mais également dans la finance en Afrique de l'Ouest (Cofina).Partenariat avec Bpifrance, bancarisation des PME, gestion des talents, intégrations régionales, investissement à impact… au micro de Tatiana Mossot, Hatim Ben Ahmed nous partage son parcours personnel et professionnel ainsi qu'une vision pour l'avenir du tissu entrepreneurial en Afrique. Notre politique de confidentialité GDPR a été mise à jour le 8 août 2022. Visitez acast.com/privacy pour plus d'informations.

In another Faculty Spotlight on Second Nature, we speak with Assistant Professor of Film and Media Studies, Hatim El-Hibri, about his 2021 book, Visions of Beirut: The Urban Life of Media Infrastructure. In this interview, Dr. El-Hibri discusses the themes of his book, his research process, the idea of concealment and how it relates to visual culture and politics, and what he hopes his book inspires other scholars to investigate within their own fields.

In Visions of Beirut: The Urban Life of Media Infrastructure (Duke UP, 2021), Hatim El-Hibri explores how the creation and circulation of images has shaped the urban spaces and cultural imaginaries of Beirut. Drawing on fieldwork and texts ranging from maps, urban plans, and aerial photographs to live television and drone-camera footage, El-Hibri traces the histories of how the technologies and media infrastructure that visualize the city are used to consolidate or destabilize regimes of power. Throughout the twentieth century, colonial, economic, and military mapping projects helped produce and govern its spaces. In the 1990s, the imagery of its post-civil war downtown reconstruction cast Beirut as a site of financial investment in ways that obscured its ongoing crises. During and following the 2006 Israel/Hizbullah war, Hizbullah's use of live television broadcasts of fighting and protests along with its construction of a war memorial museum at a former secret military bunker demonstrate the tension between visualizing space and the practices of concealment. Outlining how Beirut's urban space and public life intertwine with images and infrastructure, El-Hibri interrogates how media embody and exacerbate the region's political fault lines. Mathew Gagné in an independent writer, scholar, and educator, currently teaching in the Department of Anthropology at the University of Toronto Mississauga. Learn more about your ad choices. Visit megaphone.fm/adchoices

5. Cüz(Hatim Meal Tefsiri HDKD)

4 Hizip olarak eklendi.

TV time was so magical as kids, literally! There was Son Pari, Shararat, Hatim and a whole range of strange adventures and cringy romances. A whole buffet of stuff that was made just for us across channels running in the same time. Have you ever felt so wanted? But there is more to them than we realized! They are cooler, weirded and edgier than you remember and that's a panda promise. Follow Soumya and Ramanujan down this glorious rabbit hole to find out… how did Son Pari actually end!? On the podcast: Ramanujan and Soumya Twitter: @padhakupanda Facebook: @padhakupandapod Instagram: @padhakupanda Also available on Youtube, Spotify, Google Podcasts and Apple Podcasts! *New Episodes out every Friday! Tune in to Nerd Out* . . . . #SonPari #Hatim #Shararat #smallwonder #bewitched #karishmaKakarishma #90sKids #90sTV #90sIndia #IndianTVShows #ThrowbackThursday #IndianPodcasts #PadhakuPanda #PadhakuPandaPodcast #spotify

In the conversation, Cassie re-connects with Hatim, Planning Strategist by day, and the most wonderful singer by night. Hatim shares how his love and perspective on music and being artist has evolved, and how he balances the various demands he puts on himself. Hatim can be found on these platforms: Spotify - https://open.spotify.com/artist/75mSjc7iJmIVpLRXJiyl4v Instagram - @hatimsings Youtube - https://www.youtube.com/channel/UC7VOHHowxmo310QAnTVrLYg/videos The track you'll hear in this episode is called ‘Breathe' which is written and performed by Hatim Hanafi.

In this episode, special guest — energy healer Hatim (ig @Hatimystic & website www.hatim.co) explains to us his thoughts on energy healing, veganism, & awakening to new possibilities. He expresses his views on following your own intuition along with his personal journey through life and the result of new possibilities. Tune in !

Seerah – Life of the Prophet: Adiy Ibn Hatim becomes Muslim Episode 181 11/28/18 The post The Sīrah Podcast: EP181 – Adiy Ibn Hatim becomes Muslim appeared first on Qalam Institute.